Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of “Buy” by Analysts

Zymeworks Inc. (NASDAQ:ZYME) has received a consensus recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, one has assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $33.00.

A number of equities analysts recently commented on ZYME shares. Citizens Jmp raised shares of Zymeworks to a “strong-buy” rating in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a report on Wednesday, October 8th. Zacks Research cut Zymeworks from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Wall Street Zen downgraded Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Truist Financial raised shares of Zymeworks to a “strong-buy” rating in a research report on Wednesday, December 17th.

Zymeworks Trading Down 0.7%

NASDAQ:ZYME opened at $23.47 on Tuesday. Zymeworks has a 1-year low of $9.03 and a 1-year high of $28.49. The business has a 50-day simple moving average of $24.93. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -27.94 and a beta of 1.30.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. Zymeworks had a negative net margin of 47.16% and a negative return on equity of 19.25%. The business had revenue of $27.61 million during the quarter, compared to analyst estimates of $28.27 million.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.